Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Claudia Casali
Three Years Sustained Complete Remission Achieved in a Primary Refractory ALK-positive Anaplastic T Large Cell Lymphoma Treated With Crizotinib
Rare Tumors
Oncology
Histology
Related publications
Enteropathy-Associated Anaplastic Large T Cell Lymphoma ALK-positive (EA-ALCL-ALK+): Variant of T Cell Lymphoma With Possible Two-Hit Pathogenesis
Journal of Hematopathology
Forensic Medicine
Pathology
Hematology
Histology
Leukemic Phase of ALK-positive Anaplastic Large Cell Lymphoma
Blood
Biochemistry
Immunology
Cell Biology
Hematology
ALK-negative Anaplastic Large Cell Lymphoma
ALK-positive Anaplastic Large Cell Lymphoma With Soft Tissue Involvement in a Young Woman
OncoTargets and Therapy
Oncology
Pharmacology
Intravascular ALK-Positive Anaplastic Large-Cell Lymphoma Mimicking Inflammatory Breast Carcinoma
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Prognostic Significance of NPM-ALK Fusion Transcript Overexpression in ALK-positive Anaplastic Large-Cell Lymphoma
Modern Pathology
Forensic Medicine
Pathology
48. Mediastinal ALK-positive Anaplastic Large Cell Lymphoma in a 12-Year Old Male
Pathology
Forensic Medicine
Pathology
Primary Cutaneous Anaplastic Large Cell Lymphoma
Journal of Cutaneous Pathology
Dermatology
Forensic Medicine
Pathology
Histology
Alk Expression Plays Different Roles in Anaplastic Large-Cell Lymphomas and Outcome of Crizotinib Use in Relapsed/Refractory Alk+ Patients in a Chinese Population
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology